Cargando…

Glucocentric Drugs in Cardiovascular Disease Protection and Heart Failure

Evidence for cardiovascular outcomes with older-generation antihyperglycemic drugs in the management of type 2 diabetes is based on aggregated data from prior randomized controlled trials and observational studies that were not focused on prespecified cardiovascular end points. Newer antihyperglycem...

Descripción completa

Detalles Bibliográficos
Autores principales:	Talha, Khawaja M., Fonarow, Gregg C., Virani, Salim S., Butler, Javed
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Houston Methodist DeBakey Heart & Vascular Center 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9733124/ https://www.ncbi.nlm.nih.gov/pubmed/36561085 http://dx.doi.org/10.14797/mdcvj.1155

Ejemplares similares

SGLT-2 Inhibitors in Heart Failure: A Review of Current Evidence
por: Talha, Khawaja M., et al.
Publicado: (2023)

Breakthroughs in the treatment of heart failure with mildly reduced and preserved ejection fraction
por: Talha, Khawaja M., et al.
Publicado: (2022)

Frailty and heart failure: State‐of‐the‐art review
por: Talha, Khawaja M., et al.
Publicado: (2023)

Renin–angiotensin blockade in heart failure with preserved ejection fraction: a systematic review and meta‐analysis
por: Khan, Muhammad Shahzeb, et al.
Publicado: (2017)

The Role of Dapagliflozin in the Management of Heart Failure: An Update on the Emerging Evidence
por: Gupta, Manasvi, et al.
Publicado: (2021)

Higher risk for incident heart failure and cardiovascular mortality among community‐dwelling octogenarians without pneumococcal vaccination
por: Ahmed, Momanna B., et al.
Publicado: (2015)

Cardiovascular implications of COVID-19 versus influenza infection: a review
por: Khan, Muhammad Shahzeb, et al.
Publicado: (2020)

Discharge home health services referral and 30-day all-cause readmission in older adults with heart failure
por: Arundel, Cherinne, et al.
Publicado: (2018)

Primary Prevention of Heart Failure
por: Butler, Javed
Publicado: (2012)

Global Benefit of SGLT2 Inhibitors in Heart Failure With Reduced Ejection Fraction
por: Brownell, Nicholas K., et al.
Publicado: (2022)

The Gap to Fill: Rationale for Rapid Initiation and Optimal Titration of Comprehensive Disease-modifying Medical Therapy for Heart Failure with Reduced Ejection Fraction
por: Brownell, Nicholas K, et al.
Publicado: (2021)

Reply: Alternative Models of Cardiac Rehabilitation Delivery Urgently Needed to Improve Access for Heart Failure Patients
por: Keshvani, Neil, et al.
Publicado: (2021)

Robustness of outcomes in trials evaluating sodium–glucose co‐transporter 2 inhibitors for heart failure
por: Usman, Muhammad Shariq, et al.
Publicado: (2022)

CDC-WONDER Database Analysis of COVID-19 and Cardiovascular Disease-Related Mortality
por: Maqsood, Muhammad Haisum, et al.
Publicado: (2023)

Opportunities for Improving Global Cardiovascular Quality of Care and Outcomes
por: Fonarow, Gregg C.
Publicado: (2014)

Reporting and interpretation of subgroup analyses in heart failure randomized controlled trials
por: Khan, Muhammad Shahzeb, et al.
Publicado: (2020)

Use of Hydralazine‐Isosorbide Dinitrate Combination in African American and Other Race/Ethnic Group Patients With Heart Failure and Reduced Left Ventricular Ejection Fraction
por: Golwala, Harsh B., et al.
Publicado: (2013)

Sodium–glucose co‐transporter 2 inhibitors as an early, first‐line therapy in patients with heart failure and reduced ejection fraction
por: Tomasoni, Daniela, et al.
Publicado: (2022)

Discontinuation and non‐publication of heart failure randomized controlled trials: a call to publish all trial results
por: Khan, Muhammad Shahzeb, et al.
Publicado: (2020)

Drugs that slow the progression of diabetic kidney disease: are renoprotective effects attenuated in heart failure?
por: Packer, Milton, et al.
Publicado: (2023)

Regional Variations in Heart Failure Quality and Outcomes: Get With The Guidelines–Heart Failure Registry
por: Cunningham, Luke C., et al.
Publicado: (2021)

Overcoming Barriers to Development of Novel Therapies for Cardiovascular Disease: Insights From the Oncology Drug Development Experience
por: Khakoo, Aarif Y., et al.
Publicado: (2019)

Highlights of Cardiovascular Disease Studies Presented at the 2021 American Heart Association Scientific Sessions
por: Lee, Michelle T., et al.
Publicado: (2022)

Current and Future Drug and Device Therapies for Pediatric Heart Failure Patients: Potential Lessons from Adult Trials
por: Das, Bibhuti B., et al.
Publicado: (2021)

HEALTHCARE UTILIZATION FOR US VETERANS WITH HEART FAILURE DURING THE COVID19 PANDEMIC
por: Brownell, Nicholas Keisuke, et al.
Publicado: (2023)

Resting Heart Rate and Risk of Incident Heart Failure: Three Prospective Cohort Studies and a Systematic Meta‐Analysis
por: Khan, Hassan, et al.
Publicado: (2015)

Maternal Heart Failure
por: Bright, Rachel A., et al.
Publicado: (2021)

Insulin resistance and incident heart failure: a meta‐analysis
por: Erqou, Sebhat, et al.
Publicado: (2022)

Non‐insulin antihyperglycaemic drugs and heart failure: an overview of current evidence from randomized controlled trials
por: Savarese, Gianluigi, et al.
Publicado: (2020)

COVID-19, Heart Failure Hospitalizations, and Outcomes: A Nationwide Analysis
por: Isath, Ameesh, et al.
Publicado: (2023)

Comparison of Machine Learning Algorithms for Predicting Hospital Readmissions and Worsening Heart Failure Events in Patients With Heart Failure With Reduced Ejection Fraction: Modeling Study
por: Ru, Boshu, et al.
Publicado: (2023)

Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials
por: Fiuzat, Mona, et al.
Publicado: (2022)

Identifying patients at increased risk for poor outcomes from heart failure with reduced ejection fraction: the PROMPT‐HF risk model
por: DeVore, Adam D., et al.
Publicado: (2021)

Association between inflammatory biomarkers and adiposity in obese patients with heart failure and metabolic syndrome
por: MOTIE, MARJAN, et al.
Publicado: (2014)

Heart Failure
por: Giamouzis, Gregory, et al.
Publicado: (2011)

Health Status Disparities by Sex, Race/Ethnicity, and Socioeconomic Status in Outpatients With Heart Failure
por: Khariton, Yevgeniy, et al.
Publicado: (2018)

Lateralized Resting-State Functional Brain Network Organization Changes in Heart Failure
por: Park, Bumhee, et al.
Publicado: (2016)

Impact of an Expanded Hospital Recognition Program for Heart Failure Quality of Care
por: Heidenreich, Paul A., et al.
Publicado: (2014)

Angiotensin Receptor Neprilysin Inhibition and Associated Outcomes by Race and Ethnicity in Patients With Heart Failure With Reduced Ejection Fraction: Data From CHAMP‐HF
por: Chapman, Brittany, et al.
Publicado: (2022)

Association of Electronic Health Record Use With Quality of Care and Outcomes in Heart Failure: An Analysis of Get With The Guidelines—Heart Failure
por: Selvaraj, Senthil, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_u4vpnkpa16pmoecedo1hh5874c